- Home
- ASGN vs ELVN Comparison
ASGN vs ELVN Comparison
Compare ASGN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASGN | ELVN |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASGN | ELVN |
|---|---|---|
| Price | $19.79 | $46.13 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $38.43 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 9.7M | 983.4K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $3,980,400,000.00 | N/A |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $150.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.31 | $14.79 |
| 52 Week High | $60.06 | $48.53 |
Technical Indicators
Market Signals| Indicator | ASGN | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 18.34 | 66.36 |
| Support Level | N/A | $17.90 |
| Resistance Level | $47.94 | $48.53 |
| Average True Range (ATR) | 1.84 | 2.68 |
| MACD | -0.85 | 0.65 |
| Stochastic Oscillator | 1.21 | 94.39 |
Price Performance
Historical ComparisonAbout ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.